[go: up one dir, main page]

SV2009003373A - COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759 - Google Patents

COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759

Info

Publication number
SV2009003373A
SV2009003373A SV2009003373A SV2009003373A SV2009003373A SV 2009003373 A SV2009003373 A SV 2009003373A SV 2009003373 A SV2009003373 A SV 2009003373A SV 2009003373 A SV2009003373 A SV 2009003373A SV 2009003373 A SV2009003373 A SV 2009003373A
Authority
SV
El Salvador
Prior art keywords
difluorometoxi
phenylimidazolone
secretase
amino
ref
Prior art date
Application number
SV2009003373A
Other languages
English (en)
Inventor
Michael Sotirios
Albert Jean Robichaud
Alxander Michel Porte
Koi Michele Morris
Schuyler Adam Antane
Ji-In Kim
Robert Emmett Mcdevitt
William Ronald Solvibile
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2009003373A publication Critical patent/SV2009003373A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO 2-AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA DE LA FÓRMULA I: (VER FORMULA); LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA MÉTODOS PARA EL USO DE ESTOS PARA INHIBIR BETA-SECRETASA (BACE) Y TRATAR DEPÓSITOS BETA-AMILOIDES Y OVILLOS NEUROFIBRILARES
SV2009003373A 2007-03-20 2009-09-18 COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759 SV2009003373A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91908707P 2007-03-20 2007-03-20

Publications (1)

Publication Number Publication Date
SV2009003373A true SV2009003373A (es) 2010-08-10

Family

ID=39564223

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003373A SV2009003373A (es) 2007-03-20 2009-09-18 COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759

Country Status (24)

Country Link
US (1) US20090042964A1 (es)
EP (1) EP2137161A1 (es)
JP (1) JP2010522235A (es)
KR (1) KR20100015376A (es)
CN (1) CN101641335A (es)
AR (1) AR065811A1 (es)
AU (1) AU2008229327A1 (es)
BR (1) BRPI0808944A2 (es)
CA (1) CA2681243A1 (es)
CL (1) CL2008000784A1 (es)
CO (1) CO6140056A2 (es)
CR (1) CR11020A (es)
EC (1) ECSP099639A (es)
GT (1) GT200900241A (es)
IL (1) IL200961A0 (es)
MX (1) MX2009009699A (es)
NI (1) NI200900164A (es)
PA (1) PA8772701A1 (es)
PE (1) PE20090160A1 (es)
RU (1) RU2009133807A (es)
SV (1) SV2009003373A (es)
TW (1) TW200845965A (es)
WO (1) WO2008115552A1 (es)
ZA (1) ZA200906542B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
EP2324032B1 (en) 2008-08-19 2014-10-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2184276A1 (en) * 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
CN102348698B (zh) 2009-03-13 2015-06-03 生命医药公司 β-分泌酶的抑制剂
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
WO2014052398A1 (en) 2012-09-28 2014-04-03 Vitae Pharmaceuticals, Inc. Inhibitor of beta-secretase
ES2769578T3 (es) * 2013-02-12 2020-06-26 Buck Inst Res Aging Hidantoínas que modulan el procesamiento de APP mediado por BACE
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
WO2019209607A1 (en) * 2018-04-23 2019-10-31 Merck Sharp & Dohme Corp. Novel process for synthesis of a phenoxy diaminopyrimidine compound
CN109289696B (zh) * 2018-10-29 2022-03-22 天津先光化工有限公司 一种咪唑啉两性表面活性剂的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45198B1 (en) * 1976-06-05 1982-07-14 Wyeth John & Brother Ltd Guanidine derivatives
GB1588096A (en) * 1978-05-20 1981-04-15 Wyeth & Bros Ltd John Pyrrole derivatives
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
DE10046993A1 (de) * 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
AU2003229024A1 (en) * 2002-05-07 2003-11-11 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
DE602005012825D1 (de) * 2004-06-16 2009-04-02 Wyeth Corp Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
TW200602045A (en) * 2004-06-16 2006-01-16 Wyeth Corp Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase
RU2007126570A (ru) * 2005-01-14 2009-02-20 Вайет (Us) Аминоимидазолоны, применяемые для ингибирования бета-секретазы
RU2007124935A (ru) * 2005-02-01 2009-03-10 Вайет (Us) АМИНОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКТРЕТАЗЫ
RU2007131043A (ru) * 2005-02-14 2009-03-20 Вайет (Us) Азолилацилгуанидины, применяемые в качестве ингибиторов бета-секретазы
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
WO2006088694A1 (en) * 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
CN101213183A (zh) * 2005-06-30 2008-07-02 惠氏公司 氨基-5-(6元)杂芳基咪唑酮化合物和在β-分泌酶调节中的用途
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
EP1928841A1 (en) * 2005-09-26 2008-06-11 Wyeth a Corporation of the State of Delaware Amino-5- ý4- (difluoromethoxy) phenyl¨-5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
BRPI0620025A2 (pt) * 2005-12-19 2011-10-25 Wyeth Corp composto, método para o tratamento de uma doença ou transtorno associado a atividade excessiva de bace, método para modular a atividade de bace, composição farmacêutica e uso do composto
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
WO2008036196A2 (en) * 2006-09-21 2008-03-27 Wyeth Indolylalkylpyridin-2-amines for the inhibition of beta-secretase

Also Published As

Publication number Publication date
NI200900164A (es) 2010-07-29
BRPI0808944A2 (pt) 2014-09-02
CL2008000784A1 (es) 2008-05-30
ECSP099639A (es) 2009-10-30
EP2137161A1 (en) 2009-12-30
AU2008229327A1 (en) 2008-09-25
CN101641335A (zh) 2010-02-03
KR20100015376A (ko) 2010-02-12
AU2008229327A8 (en) 2009-10-15
CO6140056A2 (es) 2010-03-19
CR11020A (es) 2009-10-06
MX2009009699A (es) 2009-09-24
PE20090160A1 (es) 2009-02-11
GT200900241A (es) 2010-05-07
JP2010522235A (ja) 2010-07-01
WO2008115552A1 (en) 2008-09-25
AR065811A1 (es) 2009-07-01
TW200845965A (en) 2008-12-01
PA8772701A1 (es) 2008-11-19
CA2681243A1 (en) 2008-09-25
US20090042964A1 (en) 2009-02-12
IL200961A0 (en) 2010-05-17
ZA200906542B (en) 2010-06-30
RU2009133807A (ru) 2011-04-27

Similar Documents

Publication Publication Date Title
SV2009003373A (es) COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
SV2007002397A (es) Aminopiridinas como inhibidores de b-secretasa ref. am101663
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
MA32938B1 (fr) Composes organiques
CR20110440A (es) Compuestos de piridazinona
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
EA201100037A1 (ru) Органические соединения
GT200700046A (es) Nuevos microbiocidas
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
EA201270149A1 (ru) Ингибиторы bace
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CR20130024A (es) Compuestos heterocíclicos fusionados
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
MX2012012527A (es) Compuestos quimicos.
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
BRPI0921868A2 (pt) inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica
CO6362013A2 (es) Derivados de rifamicina
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
CL2007000773A1 (es) Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.

Legal Events

Date Code Title Description
FD Lapse